At a glance
Effects
- Rapid fat-mass reduction (preclinical): Obese rhesus monkeys lost ~10.6–11% of body weight and ~39% of fat deposits over 28 days of daily dosing, confirmed by MRI/DEXA; obese mice lost ~30%. No human efficacy has ever been demonstrated.[6][3][2]
- Improved insulin sensitivity (preclinical): Treated obese monkeys and mice showed improved insulin resistance and glucose tolerance, sometimes within days, in animal models only.[2][6]
- Non-hormonal mechanism: Acts on adipose vasculature rather than growth hormone, thyroid, appetite or metabolic hormones, so it does not cause classic hormonal side effects.[4]
Experimental peptidomimetic (vascular-targeting proapoptotic peptide)
Subcutaneous injection (route used in primate studies)
Not FDA-approved; no legal human-use pathway
Discontinued 2019 after Phase 1 (nephrotoxicity)
Dose-dependent kidney (renal tubule) injury
About Adipotide
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Adipotide (also called Prohibitin-Targeting Peptide 1 / Prohibitin-TP01 or FTPP, "Fat-Targeted Proapoptotic Peptide") is an experimental peptidomimetic studied as an anti-obesity agent that selectively destroys the blood supply of white fat tissue.[1][3] It is NOT an approved drug — its only human trial was a Phase 1 study in prostate-cancer patients, and clinical development was discontinued in 2019.[5][7]
How it works
Adipotide is a two-part molecule (sequence CKGGRAKDC-GG-D(KLAKLAK)2): a homing sequence that binds the receptor prohibitin (and annexin A2) found on the blood vessels feeding white adipose tissue, fused to a pro-apoptotic peptide that disrupts mitochondrial membranes once the cell internalises it.[2][1] By killing the endothelial cells that supply fat, it starves the fat cells of their blood supply so they die and are reabsorbed — a "vascular-targeting" mechanism unlike hormonal or appetite-based weight-loss drugs.[2][6]
Risks & side effects
Most important: The dominant danger is kidney damage: dose-dependent renal proximal-tubule injury was the primary side effect in primate studies, and the human Phase 1 trial was terminated for nephrotoxicity, with the proapoptotic payload thought to harm renal tubular cells as the kidney clears the peptide.[6][8] Renal effects were "predictable, dose-dependent and reversible" in monkeys, but the human therapeutic window between effective and kidney-damaging doses proved too narrow, and no human safety profile was ever established.[7][5]
Common
Serious
Safety & harm reduction
- Anyone — there is no approved human indication and no population for whom use is supported by evidence[7]
- People with pre-existing kidney disease or reduced renal function (renal tubular toxicity was the dose-limiting effect)[7]
- People with active or suspected cancer (prohibitin/vascular-targeting mechanism uncharacterised in human tumour vasculature)[7]
- Because the primary toxicity is renal, baseline and ongoing kidney monitoring would be essential to any use, but this does not make it safe given the terminated human trial[6][7]
- Products sold online are unregulated and have been found contaminated, misdosed or misidentified — identity, purity and dose cannot be assumed[7]
Dosage context
No human dose has ever been established and there is no prescription form. The only primate data used ~0.43 mg/kg subcutaneously daily (with reported ranges up to ~0.5–1.0 mg/kg/day) for 28 days, at which doses dose-dependent kidney toxicity appeared — these are animal-research figures, not a human prescription, and the human therapeutic window proved too narrow for safe use.[2][5] Any quoted "protocol" online is extrapolated from animal studies and is not validated for human safety.[7]
Sources
- 1.Barnhart et al. 2011, Science Translational Medicine — peptidomimetic targeting white fat in obese monkeys (PMC)
- 2.Wikipedia — Prohibitin-targeting peptide 1 (Adipotide)
- 3.ScienceDaily — Obese monkeys lose weight on fat-blood-supply drug
- 4.Muscle and Brawn — Adipotide fat-loss peptide overview
- 5.PeptideInsight — Adipotide research evidence & safety profile
- 6.PeptideDeck — Adipotide (FTPP) guide (kidney toxicity, dosing)
- 7.Superpower — Adipotide proapoptotic peptide guide (legal/regulatory status)
- 8.Arrowhead Pharmaceuticals — Phase 1 trial dosing announcement (link unavailable)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Adipotide· 3 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Generic | vial | 5 mg | 10 vial | 239,99 € | — |
Generic | vial | 10 mg | 10 vial | 339,99 € | — |
GenericSelected | vial | 10 mg | 10 vial | 359,99 € | — |